Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Hoffmann-La Roche is the lead sponsor of 186 current clinical trials in our USA, UK, China, India, Ireland and EU (CTIS) registers. 62 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Atezolizumab, Tocilizumab and Inavolisib. The most-studied condition is Breast Cancer.

Company profiles on this site (news, sites, medicines, approvals): Roche Holding AG (CH) →Roche Ireland (IE) →

ClinicalTrials.gov trials by status

Recruiting6235%
Active, closed11365%

Trials by phase

Phase 38046%
Phase 23520%
Phase 1/22011%
Phase 11911%
Observational116%
Phase 463%
Phase 2/342%

Clinical trials sponsored by Hoffmann-La Roche

175 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer NCT07287150 · Metastatic Castration-Resistant Prostate Cancer Drugs: Abiraterone, Docetaxel, Enzalutamide	Phase 2	Recruiting	2026-03	UK, USA
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis NCT06588855 · Moderately to Severely Active Ulcerative Colitis Drug: Afimkibart	Phase 3	Recruiting	2024-12	UK, USA, India, China
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer NCT07405801 · Breast Cancer Drugs: Fulvestrant, Inavolisib, Ribociclib	Phase 2	Recruiting	2026-04	UK, USA
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) NCT05199688 · Neuromyelitis Optica Spectrum Disorder, NMOSD Drug: Satralizumab	Phase 3	Recruiting	2026-05	UK, USA, China
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06793215 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer Drugs: Carboplatin, Cisplatin, Divarasib	Phase 3	Recruiting	2025-10	Ireland, UK, USA, China
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study NCT05862285 · Cancer Drugs: Atezolizumab, Bevacizumab, Divarasib	Phase 3	Recruiting	2023-06	UK, China
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer NCT05894239 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer Drugs: Inavolisib, Phesgo	Phase 3	Recruiting	2023-09	UK, USA, India, China
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy NCT07588100 · Diabetic Retinopathy	Phase 1	Recruiting	2026-06	USA
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease NCT07174310 · Parkinson's Disease Drug: Prasinezumab	Phase 3	Recruiting	2025-11	UK, USA, China
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis NCT07158242 · ClinicalTrials.gov ↗ · Moderately to Severely Active Ulcerative Colitis Drug: Afimkibart	Phase 3	Recruiting	2026-04	UK, USA, China
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy NCT05646862 · Breast Cancer Drugs: Alpelisib, Bupropion, Fulvestrant	Phase 3	Recruiting	2023-06	UK, USA, China
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease NCT06819878 · ClinicalTrials.gov ↗ · Moderately to Severely Active Crohns Disease Drug: Afimkibart	Phase 3	Recruiting	2025-03	UK, USA, India, China
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) NCT04929223 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer Drugs: Atezolizumab, Bevacizumab, Cetuximab	Phase 1	Recruiting	2021-10	UK, USA
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation NCT05789082 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Divarasib	Phase 1/2	Recruiting	2023-06	UK, USA, China
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease NCT07717411 · ClinicalTrials.gov ↗ · Alzheimer's Disease Drug: Trontinemab	Phase 3	Recruiting	2026-11	UK, USA, China
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease NCT06819891 · ClinicalTrials.gov ↗ · Moderately to Severely Active Crohns Disease Drug: Afimkibart	Phase 3	Recruiting	2025-05	UK, USA, India, China
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy NCT06862869 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drug: Alectinib	Observational	Recruiting	2025-04	China
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer NCT04802759 · Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer Drugs: Abemaciclib, Atezolizumab, Everolimus	Phase 1/2	Recruiting	2021-06	USA
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies NCT06274515 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Recruiting	2024-04	UK
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A NCT07416604 · ClinicalTrials.gov ↗ · Hemophilia A Drug: Emicizumab	Phase 3	Recruiting	2026-04	UK, USA, China
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes NCT07670416 · ClinicalTrials.gov ↗ · Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)	Phase 3	Recruiting	2026-07	China
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease NCT07298421 · ClinicalTrials.gov ↗ · Moderately to Severely Active Crohns Disease Drug: Afimkibart	Phase 3	Recruiting	2026-08	UK, USA
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice NCT07284121 · ClinicalTrials.gov ↗ · Lung Cancer, Hepatocellular Carcinoma Drug: Atezolizumab	Observational	Recruiting	2025-07	UK
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease NCT06998524 · ClinicalTrials.gov ↗ · Von Willebrand Disease, Type 3 Drug: Emicizumab	Phase 3	Recruiting	2025-06	UK, USA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Drugs: Mosunetuzumab, Rituximab, Tocilizumab	Phase 1	Recruiting	2022-03	UK, USA, China
An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis NCT07620392 · Rheumatoid Arthritis Drug: Afimkibart	Phase 2	Recruiting	2026-06	USA
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma NCT07555938 · Multiple Myeloma Drugs: Carfilzomib, Cevostamab, Daratumumab	Phase 3	Recruiting	2026-06	USA, China
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy NCT05861999 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal Drug: Risdiplam	Phase 4	Recruiting	2024-08	UK, USA
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive NCT07413939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drugs: Capecitabine, Trastuzumab, Tucatinib	Phase 2/3	Recruiting	2026-05	UK, USA, China
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma NCT07200375 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma Drug: Glofitamab	Observational	Recruiting	2025-09	China
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) NCT07282574 · ClinicalTrials.gov ↗ · Progressive Multiple Sclerosis Drug: Ocrelizumab	Phase 2	Recruiting	2026-03	UK
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants NCT05039619 · ClinicalTrials.gov ↗ · Lupus Nephritis Drugs: Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone	Phase 2	Recruiting	2022-05	UK, USA
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A NCT05987449 · ClinicalTrials.gov ↗ · Hemophilia A	Phase 1/2	Recruiting	2023-09	USA
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer NCT03424005 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer Drugs: Abemaciclib, Atezolizumab, Atirmociclib	Phase 1/2	Recruiting	2018-03	UK, USA
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A NCT07416526 · ClinicalTrials.gov ↗ · Hemophilia A	Phase 3	Recruiting	2026-05	UK, USA
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma NCT06084936 · ClinicalTrials.gov ↗ · Lymphoma Drugs: Bendamustine, Glofitamab, Lenalidomide	Phase 3	Recruiting	2023-10	UK, USA, China
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes NCT07351045 · ClinicalTrials.gov ↗ · Obesity or Overweight	Phase 3	Recruiting	2026-03	UK, USA, China
Extension Study for the Port Delivery System With Ranibizumab (Portal) NCT03683251 · ClinicalTrials.gov ↗ · Neovascular Age-Related Macular Degeneration Drug: PDS Implant with Ranibizumab	Phase 3	Recruiting	2018-09	UK, USA
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes NCT07351058 · ClinicalTrials.gov ↗ · Obesity or Overweight, Type 2 Diabetes Mellitus	Phase 3	Recruiting	2026-03	UK, USA, China
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy NCT05861986 · ClinicalTrials.gov ↗ · Muscular Atrophy, Spinal Drug: Risdiplam	Phase 4	Recruiting	2024-05	UK, USA
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD NCT06847542 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration Drug: Ranibizumab	Phase 3	Recruiting	2025-11	UK
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis NCT07665723 · ClinicalTrials.gov ↗ · Active Ulcerative Colitis Drugs: Afimkibart, Caffeine, Midazolam	Phase 1	Recruiting	2026-06	UK, USA
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer NCT06790693 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: CDK4/6i, Inavolisib, Letrozole	Phase 3	Recruiting	2025-04	UK, USA, China
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer NCT07368998 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Fulvestrant, Inavolisib	Phase 2	Recruiting	2026-02	UK, USA
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) NCT07137598 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis Drug: Afimkibart	Phase 2	Recruiting	2025-12	UK, USA
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts NCT06094010 · ClinicalTrials.gov ↗ · Influenza Drug: Baloxavir Marboxil	Phase 3	Recruiting	2023-11	USA
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis NCT07223697 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: Afimkibart	Phase 2	Recruiting	2026-01	USA
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600 · ClinicalTrials.gov ↗ · Locally Advanced Breast Cancer, Metastatic Breast Cancer Drugs: Fulvestrant, Inavolisib, Palbociclib	Observational	Recruiting	2026-01	China
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A NCT07226206 · ClinicalTrials.gov ↗ · Hemophilia A	Phase 1/2	Recruiting	2026-09	USA
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma NCT05954910 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma Drug: Polatuzumab Vedotin	Observational	Recruiting	2023-08	China
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) NCT07541170 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Divarasib, Nivolumab, Opdivo	Phase 3	Recruiting	2026-09	USA
A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Monitoring the Development of Secondary Events in Patients Diagnosed With Traumatic Brain Injury NCT07455136 · ClinicalTrials.gov ↗ · Traumatic Brain Injury	Observational	Recruiting	2026-02	USA
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775 · ClinicalTrials.gov ↗ · Mature B-Cell Non-Hodgkin Lymphoma Drugs: Carboplatin, Etoposide, Glofitamab	Phase 1/2	Recruiting	2022-11	USA, China
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies NCT07177352 · ClinicalTrials.gov ↗ · Alzheimers Disease	Phase 3	Recruiting	2025-07	USA, China
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma NCT06624085 · ClinicalTrials.gov ↗ · Lymphoma Drugs: Gemcitabine, Glofitamab, Obinutuzumab	Phase 1	Recruiting	2025-04	USA
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer NCT07054190 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Giredestrant, Inavolisib, Letrozole	Phase 2	Recruiting	2025-09	USA
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) NCT06884618 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	2025-04	USA, China
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) NCT07416552 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 1	Recruiting	2026-09	USA
A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions NCT07741604 · ClinicalTrials.gov ↗ · Renal Impairment Drug: RO7795081	Phase 1	Recruiting	2026-09	USA
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033 · ClinicalTrials.gov ↗ · Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma Drugs: Gemcitabine, Glofitamab, Obinutuzumab	Phase 2	Recruiting	2025-03	USA
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease NCT06826612 · ClinicalTrials.gov ↗ · Huntington Disease	Phase 1/2	Recruiting	2025-02	USA
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants NCT07626515 · ClinicalTrials.gov ↗ · Healthy Participants	Phase 1	Recruiting	2026-07	China
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) NCT04544436 · Multiple Sclerosis Drugs: Methylprednisolone, Ocrelizumab	Phase 3	Active, closed	2020-11	UK, USA
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration NCT06795048 · Neovascular Age-related Macular Degeneration (nAMD) Drug: Faricimab	Phase 4	Active, closed	2025-03	UK, USA, China
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options NCT02650401 · Solid Tumors, CNS Tumors Drug: Entrectinib	Phase 1/2	Active, closed	2016-05	UK, USA, China
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer NCT05047250 · Non-Small Cell Lung Cancer Drug: Atezolizumab	Phase 3	Active, closed	2022-06	China
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity NCT06965413 · Obesity, Overweight, Overweight With One Weight Related Comorbidity Drugs: RO7204239, Tirzepatide	Phase 2	Active, closed	2025-05	UK, USA
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer NCT05009069 · Rectal Neoplasms, Rectal Cancer Drugs: Atezolizumab, Capecitabine, Fluorouracil	Phase 2	Active, closed	2022-03	China
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) NCT05123703 · Relapsing-remitting Multiple Sclerosis Drugs: Fingolimod, Ocrelizumab	Phase 3	Active, closed	2022-05	UK, USA, India
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy NCT04873362 · Breast Cancer Drugs: Atezolizumab, Trastuzumab, Trastuzumab emtansine	Phase 3	Active, closed	2021-05	UK, USA, India, China
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) NCT05170204 · Non-Small Cell Lung Cancer Drugs: Alectinib, Durvalumab, Entrectinib	Phase 3	Active, closed	2022-11	UK, USA, China
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) NCT06680817 · Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Drug: Faricimab	Observational	Active, closed	2025-02	Ireland
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis NCT04035005 · Multiple Sclerosis, Primary Progressive Drug: Ocrelizumab	Phase 3	Active, closed	2019-08	UK, USA
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) NCT06065748 · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Drugs: Abemaciclib, Fulvestrant, Giredestrant	Phase 3	Active, closed	2023-12	USA, India, China
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis NCT03523858 · ClinicalTrials.gov ↗ · Progressive Multiple Sclerosis (PMS) Drug: Ocrelizumab	Phase 3	Active, closed	2018-05	Ireland, USA
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy NCT04660344 · ClinicalTrials.gov ↗ · Muscle-invasive Bladder Cancer Drug: Atezolizumab	Phase 3	Active, closed	2021-05	Ireland, UK, USA, China
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus NCT05835986 · Systemic Lupus Erythematosus Drug: Tocilizumab	Phase 1	Active, closed	2023-12	UK
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases NCT04603807 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung Drugs: Crizotinib, Entrectinib	Phase 3	Active, closed	2021-09	India, China
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products NCT05476926 · Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion Drug: Faricimab	Observational	Active, closed	2022-11	UK, USA
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) NCT04861259 · ClinicalTrials.gov ↗ · Atypical Hemolytic Uremic Syndrome Drug: Crovalimab	Phase 3	Active, closed	2021-10	USA, India, China
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · Non-Small Cell Lung Cancer Drugs: Alectinib, Atezolizumab, Bevacizumab	Phase 2/3	Active, closed	2017-09	USA, China
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease NCT07170150 · Alzheimers Disease Drug: Trontinemab	Phase 3	Active, closed	2025-11	UK, USA
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) NCT06402838 · Alzheimer's Disease	Phase 2	Active, closed	2024-05	UK
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer NCT03456076 · Carcinoma, Non-Small-Cell Lung Drugs: Carboplatin, Cisplatin, Gemcitabine	Phase 3	Active, closed	2018-08	UK, USA, China
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) NCT04961996 · ClinicalTrials.gov ↗ · Early Breast Cancer Drug: Giredestrant	Phase 3	Active, closed	2021-08	Ireland, UK, USA, India, China
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma NCT03075696 · Non-Hodgkin's Lymphoma Drugs: Glofitamab, Obinutuzumab, Tocilizumab	Phase 1/2	Active, closed	2017-02	USA, China
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) NCT04586023 · ClinicalTrials.gov ↗ · Relapsing Multiple Sclerosis Drugs: Fenebrutinib, Teriflunomide	Phase 3	Active, closed	2021-03	UK, USA, India
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis NCT05181618 · Severe Hemophilia A, Moderate Hemophilia A Drug: Emicizumab	Phase 4	Active, closed	2022-06	UK, USA
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression NCT05797610 · Primary IgA Nephropathy	Phase 3	Active, closed	2023-08	UK, USA, China
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease NCT05595642 · ClinicalTrials.gov ↗ · Chronic Obstructive Pulmonary Disease (COPD) Drug: Astegolimab	Phase 3	Active, closed	2022-12	UK, USA, India, China
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors NCT04432584 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria Drugs: Crovalimab, Eculizumab	Phase 3	Active, closed	2020-09	Ireland, UK, USA
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis NCT04075266 · Multiple Sclerosis Drug: Ocrelizumab	Phase 2	Active, closed	2020-01	USA
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma NCT05535244 · Multiple Myeloma Drugs: Cevostamab, Tocilizumab	Phase 1/2	Active, closed	2022-10	USA
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study NCT04589845 · ClinicalTrials.gov ↗ · Solid Tumors Drugs: Alectinib, Atezolizumab, Belvarafenib	Phase 2	Active, closed	2021-01	UK, USA, China
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis NCT06863961 · Atopic Dermatitis Drug: Afimkibart	Phase 2	Active, closed	2025-04	USA
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease NCT05686551 · ClinicalTrials.gov ↗ · Huntington Disease	Phase 2	Active, closed	2023-02	UK, USA
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease NCT04639050 · ClinicalTrials.gov ↗ · Alzheimers Disease Drug: Trontinemab	Phase 1/2	Active, closed	2021-03	UK, USA
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) NCT06128564 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy	Phase 2	Active, closed	2023-11	UK
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer NCT05645692 · ClinicalTrials.gov ↗ · Urothelial Cancer Drugs: Atezolizumab, Tiragolumab, Tobemstomig	Phase 2	Active, closed	2023-04	UK, USA, China
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus NCT04963296 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus Drugs: Acetaminophen/Paracetamol, Diphenhydramine hydrochloride, Methylprednisolone	Phase 3	Active, closed	2021-10	UK, USA

Showing the 100 most recently updated of 175 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Hoffmann-La Roche in the EU trials register (CTIS)

11 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Hoffmann-La Roche as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors 2026-525215-13-00 · Neoplasms	Phase 1	Authorised	Spain, Poland, Romania + 7 more
A Study to See How a New Compound, Trontinemab Affects the Body and Whether Immune Signals Triggered by it Affect How Other Medicines are Processed 2026-526756-31-00 · Mental Disorders	Phase 1	Authorised	Germany
A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY 2026-525736-42-00 · Neoplasms Drugs: Cevostamab, Dexamethasone, Pomalidomide	Phase 2	Ongoing	Germany
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy 2025-524028-23-00 · CTIS ↗ · Neoplasms Drugs: Carfilzomib, Cevostamab, Daratumumab	Phase 3	Ongoing	France, Germany, Italy + 5 more
An Open-Label Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis 2025-524164-37-00 · CTIS ↗ · Nervous System Diseases Drug: Ocrelizumab	Phase 2	Authorised	Poland, Germany, France
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS 2025-522434-32-00 · CTIS ↗ · Congenital, Hereditary, and Neonatal Diseases and Abnormalities	Phase 3	Ongoing	France, Austria, Poland + 6 more
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials 2025-523579-47-00 · CTIS ↗ · Immune System Phenomena Drug: Afimkibart	Phase 2	Ongoing	Italy, Spain, Germany + 4 more
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases 2025-524498-17-00 · CTIS ↗ · Neoplasms Drugs: Capecitabine, Trastuzumab, Tucatinib	Phase 3	Ongoing	Belgium, France, Italy + 8 more
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors 2025-521034-28-00 · CTIS ↗ · Immune System Phenomena Drug: Afimkibart	Phase 2	Ongoing	Italy, Denmark, France + 4 more
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants with Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) 2024-518006-40-00 · CTIS ↗ · Nervous System Diseases Drug: Trontinemab	Phase 3	Ongoing	Spain, Poland, Italy + 3 more
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants with Advanced Solid Tumors 2024-519622-20-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Germany, Netherlands, Spain + 3 more

Drugs in Hoffmann-La Roche trials

129 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 89 more in the trial list above.

Conditions in Hoffmann-La Roche trials

119 conditions

Breast Cancer10 Non-Small Cell Lung Cancer7 Multiple Sclerosis7 Neovascular Age-related Macular Degeneration5 Diabetic Macular Edema4 Solid Tumors4Alzheimers Disease4Relapsing Multiple Sclerosis4 Hemophilia A4 Paroxysmal Nocturnal Hemoglobinuria3 Alzheimer's Disease3 Carcinoma, Non-Small-Cell Lung3 Cancer3Moderately to Severely Active Ulcerative Colitis3Metastatic Breast Cancer3Moderately to Severely Active Crohns Disease3Muscular Atrophy, Spinal3Lymphoma3 Multiple Myeloma3KRAS G12C Lung Cancer2Neovascular Age-related Macular Degeneration (nAMD)2 Obesity2 Overweight2Multiple Sclerosis, Primary Progressive2

By trial register

Register	Trials	Recruiting
Clinical trials in USA	140	51
Clinical trials in UK	105	37
Clinical trials in China	84	29
Clinical trials in India	16	4
Clinical trials in Ireland	6	1
EU register (CTIS)	11	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Ruijin Hospital	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about Hoffmann-La Roche trials

How many clinical trials does Hoffmann-La Roche sponsor?

Hoffmann-La Roche is the lead sponsor of 175 current trials on ClinicalTrials.gov in our USA, UK, China, India and Ireland registers, and 11 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hoffmann-La Roche trials recruiting?

Yes. 62 of its 175 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hoffmann-La Roche testing?

Its current trials name 129 drugs and biologicals as interventions. The most frequent are Atezolizumab (24), Tocilizumab (18), Inavolisib (16), Afimkibart (15) and Obinutuzumab (14). The number in brackets is how many of its trials name each drug.

Does Hoffmann-La Roche have clinical trials in Ireland?

Yes. 6 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Hoffmann-La Roche clinical trials